Seroprevalence of Hepatitis A Virus in Pediatric Patients with Hematologic Malignancies after Chemotherapy and Hematopoietic Cell Transplantation
- Author:
Ja Un MOON
1
;
A Luem HAN
;
Eui Soo LEE
;
Seong koo KIM
;
Seung Beom HAN
;
Jae Wook LEE
;
Nack Gyun CHUNG
;
Bin CHO
;
Dae Chul JEONG
;
Jin Han KANG
Author Information
- Publication Type:Brief Communication
- From:Infection and Chemotherapy 2019;51(2):183-187
- CountryRepublic of Korea
- Language:English
- Abstract: This retrospective study was performed to determine the seroprevalence of hepatitis A virus (HAV) in children and adolescents with hematologic malignancies after the completion of chemotherapy and hematopoietic cell transplantation (HCT). Of 97 enrolled patients, 60 (61.9%) were seropositive for HAV. The seroprevalences in patients undergoing chemotherapy and HCT were 60.3% (41/68) and 65.5% (19/29), respectively (P = 0.628). No significant factors associated with seropositivity for HAV after chemotherapy and HCT were identified. Anti-HAV tests and HAV re-vaccinations can be considered in children and adolescents with underlying hematologic malignancies after chemotherapy and HCT based on the anti-HAV results.
